These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. On decreasing distal endothelial damage after intracoronary shunt insertion. Demaria RG; Perrault LP Ann Thorac Surg; 2005 May; 79(5):1826. PubMed ID: 15855002 [No Abstract] [Full Text] [Related]
29. Case presentation of doxorubicin-induced cardiomyopathy: a short- and long-term side effect of pediatric cancer treatment. Dunn J J Pediatr Oncol Nurs; 1991 Apr; 8(2):84. PubMed ID: 1675089 [No Abstract] [Full Text] [Related]
30. Stabilization of chronic remodeling by asynchronous cardiomyoplasty in dilated cardiomyopathy: effects of a conditioned muscle wrap. Patel HJ; Polidori DJ; Pilla JJ; Plappert T; Kass D; St John Sutton M; Lankford EB; Acker MA Circulation; 1997 Nov; 96(10):3665-71. PubMed ID: 9396469 [TBL] [Abstract][Full Text] [Related]
31. Does a suitable animal model for research on partial left ventriculectomy exist? Animal models for PLV. Christiansen S; Jahn UR; Stypmann J; Redmann K; Scheld HH; Hammel D Thorac Cardiovasc Surg; 2001 Oct; 49(5):259-67. PubMed ID: 11605134 [TBL] [Abstract][Full Text] [Related]
32. Naturally occurring cardiomyopathy in the Doberman pinscher: a possible large animal model of human cardiomyopathy? Smucker ML; Kaul S; Woodfield JA; Keith JC; Manning SA; Gascho JA J Am Coll Cardiol; 1990 Jul; 16(1):200-6. PubMed ID: 2358594 [TBL] [Abstract][Full Text] [Related]
33. Long term survival after heart transplantation for doxorubicin induced cardiomyopathy. Aricò M; Pedroni E; Nespoli L; Viganò M; Porta F; Burgio GR Arch Dis Child; 1991 Aug; 66(8):985-6. PubMed ID: 1929498 [TBL] [Abstract][Full Text] [Related]
34. The effects of isoflurane and halothane on left ventricular afterload in dogs with dilated cardiomyopathy. Hettrick DA; Pagel PS; Kersten JR; Lowe D; Warltier DC Anesth Analg; 1997 Nov; 85(5):979-86. PubMed ID: 9356087 [TBL] [Abstract][Full Text] [Related]
35. Induction of heart failure: haemodynamic comparison of three different canine models. Djelmami-Hani M; Kazemi S; Hare J; Chekanov VS Lab Anim; 2007 Jan; 41(1):63-70. PubMed ID: 17234051 [TBL] [Abstract][Full Text] [Related]
36. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. O'Connell JL; Romano MM; Campos Pulici EC; Carvalho EE; de Souza FR; Tanaka DM; Maciel BC; Salgado HC; Fazan-Júnior R; Rossi MA; Simões MV Exp Toxicol Pathol; 2017 Apr; 69(4):213-219. PubMed ID: 28153388 [TBL] [Abstract][Full Text] [Related]
37. Cardioprotective effect of grape-seed proanthocyanidins on doxorubicin-induced cardiac toxicity in rats. Ammar el-SM; Said SA; El-Damarawy SL; Suddek GM Pharm Biol; 2013 Mar; 51(3):339-44. PubMed ID: 23134235 [TBL] [Abstract][Full Text] [Related]
38. Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Power JM; Raman J; Dornom A; Farish SJ; Burrell LM; Tonkin AM; Buxton B; Alferness CA Cardiovasc Res; 1999 Dec; 44(3):549-55. PubMed ID: 10690287 [TBL] [Abstract][Full Text] [Related]
39. Effects of acute dynamic cardiomyoplasty in a goat model of chronic ventricular dilatation: part 1. Bolotin G; Lorusso R; Schreuder JJ; Kaulbach HG; Uretzky G; van der Veen FH Ann Thorac Surg; 2002 Aug; 74(2):507-13. PubMed ID: 12173837 [TBL] [Abstract][Full Text] [Related]
40. Heart rate dynamics in doxorubicin-induced cardiomyopathy. Lončar-Turukalo T; Vasić M; Tasić T; Mijatović G; Glumac S; Bajić D; Japunžić-Žigon N Physiol Meas; 2015 Apr; 36(4):727-39. PubMed ID: 25798626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]